[The Evidence for the Treatment of Polypoidal Choroidal Vasculopathy]
Abstract:
The optimal treatment of polypoidal choroidal vasculopathy (PCV) is still undetermined. Photodynamic therapy (PDT) is effective for PCV but the Treatment effect declines after one year. While some reports show the efficacy of anti-vascular endothelial growth factor (VEGF) therapy for PCV, other reports show treatment-refractory cases. In this article, the author reviews the results of our multicenter randomized trial, conducted to compare the efficacy of PDT and ranibizumab in PCV patients. The results showed that ranibizumab is more effective in visual gain in two-year follow up. Central retinal thickness improved with both treatments and there was no difference between them. Our results provide evidence that ranibizumab is superior to PDT monotherapy for treatment of PCV in terms of visual acuity.
More Related Videos
10:24Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
11:20Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Glaucoma: Overview
